MEDICAL ONCOLOGY

CLOSED TO RECRUITMENT — AUSTRALIA

Abbrev. Title

ANZUP1907

Protocol Title

RetrospectivePSMA: a Retrospective Study to Identify Clinical Predictors of Early Metastatic Disease Using PSMA PET Imaging

B9991001 JAVELIN100 A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study, of Avelumab (MSB0010718C) plus Best Supportive Care versus Best Supportive Care Alone as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion of Frist-Line PlatinumContaining Chemotherapy

B9991001 JAVELIN100 A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study, of Avelumab (MSB0010718C) plus Best Supportive Care versus Best Supportive Care Alone as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion of Frist-Line PlatinumContaining Chemotherapy

B9991009 JAVELIN200 A Study of Avelumab Alone or in Combination with Pegylated Liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin Alone in Patients with Platinum Resistant/ Refractory Ovarian Cancer

BCRC122 RAPPER Review of Australian Prescribing Practices of Eribulin

BGB-290-103 Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumours

BGB-900-103 A Phase 1B Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Sitravatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumours

BO25126 APHINITY A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy plus Trastuzumab plus Placebo versus Chemotherapy plus Trastuzumab plus Pertuzumab as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer

BO28407 KAITLIN A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines As Adjuvant Therapy In Patients With Operable HER2-Positive Primary Breast Cancer